If you’re exploring ways to boost your digestive and overall health, understanding the role of this probiotic can offer valuable insight.

Akkermansia muciniphila is a beneficial bacterium that naturally resides in the mucus layer of the human gut, where it feeds on mucin, a protein that helps maintain the integrity of the gut lining. First discovered in 2004, it has gained attention for its association with better metabolic health, immune balance and weight regulation.

Unlike many other probiotic strains, Akkermansia muciniphila isn’t commonly found in fermented foods. Instead, it occurs naturally in healthy human microbiomes and is now available in Akkermansia probiotic supplements designed to restore or increase its population.

One of the primary benefits of Akkermansia muciniphila is its role in strengthening the gut barrier. It feeds on mucin, stimulating the production of more mucin, which helps maintain the thickness of the gut’s protective mucus layer.

A healthy gut barrier is crucial for preventing “leaky gut,” a condition linked to inflammation and autoimmune disorders.

Low levels of Akkermansia have been associated with gut dysbiosis and increased intestinal permeability, while higher levels correlate with stronger mucosal integrity.

Akkermansia muciniphila has been shown to improve insulin sensitivity and support balanced blood sugar levels. In one study published in Nature Medicine, for example, overweight or obese individuals who took pasteurized Akkermansia supplements experienced improvements in insulin sensitivity and reductions in markers of liver dysfunction.

This benefit makes the Akkermansia probiotic a promising tool for managing metabolic conditions, such as prediabetes and type 2 diabetes.

Researchers have discovered that people with higher levels of Akkermansia muciniphila tend to have lower body fat percentages and healthier weights. This bacterium helps regulate fat storage and appetite by producing short-chain fatty acids like acetate and propionate, which support satiety and fat metabolism.

A 2019 human trial revealed that individuals who supplemented with this probiotic experienced modest weight loss and reduced waist circumference compared to those who did not.

Chronic, low-grade inflammation contributes to many health conditions, including obesity, heart disease and autoimmune disorders. Akkermansia muciniphila may help modulate immune responses and reduce inflammation by maintaining gut integrity and influencing cytokine production.

Studies have shown that increased levels of this probiotic are associated with lower concentrations of inflammatory markers, such as C-reactive protein, and greater anti-inflammatory cytokine activity.

Emerging evidence suggests that Akkermansia levels decline with age, potentially contributing to age-related diseases. By improving gut health and reducing systemic inflammation, Akkermansia muciniphila may promote healthier aging.

A systematic review of human studies on the gut microbiome and longevity found that this unique probiotic is one of the few microbial genera consistently increased in the oldest adults, especially centenarians, in comparison to younger elderly groups. These individuals also demonstrated higher microbial diversity and enhanced functional features related to short-chain fatty acid production and anti-inflammatory pathways, traits associated with longevity and resilience to age-related disease.

In simpler terms, cross‑sectional data from multiple human aging studies have shown that higher levels of Akkermansia muciniphila correlate with advanced age in healthy individuals, particularly those who are exceptionally long-lived. This suggests that the presence of this probiotic may contribute to gut barrier integrity, reduced systemic inflammation and metabolic balance, all key factors that support healthspan and may favor longevity.

Emerging research suggests that Akkermansia muciniphila (A. muciniphila) may support brain health by modulating the gut-brain axis.

In a 2024 case-control study published in Microbiome, researchers analyzed fecal microbiomes from 97 patients with liver cirrhosis (58 without hepatic encephalopathy, 39 with HE) and compared them to 57 healthy controls, plus 48 individuals with cognitive impairment and 32 cognitively normal individuals. They found that the relative abundance of A. muciniphila was significantly reduced in cognitively impaired individuals compared to controls and showed a positive correlation with cognitive scores.

This suggests that lower levels of A. muciniphila are associated with worse cognitive performance in humans.

A. muciniphila may also benefit mental health. Preclinical models have shown that boosting levels of this probiotic can reduce anxiety-like behavior, possibly by lowering inflammation and balancing neurotransmitters via the gut-brain connection.

Though human studies are still in early stages, the findings are promising.

In addition to improving insulin sensitivity, Akkermansia muciniphila may contribute to better glucose regulation. Several studies have indicated that its presence is associated with lower fasting blood glucose and improved glycemic control, particularly in individuals with metabolic syndrome or prediabetes.

Unlike many traditional probiotics, such as Lactobacillus or Bifidobacterium, Akkermansia muciniphila:

Moreover, pasteurized forms of Akkermansia may offer enhanced effects, as studies suggest that heat-treated bacteria retain immune-modulating properties without the risk of overgrowth.

While you can’t consume Akkermansia muciniphila directly from food, certain dietary choices help stimulate its growth:

For those with low levels or gut imbalances, Akkermansia probiotic supplements can help restore this beneficial microbe. These are typically formulated with pasteurized or encapsulated Akkermansia muciniphila to ensure viability and safety.

Look for products supported by clinical research and manufactured with third-party testing to ensure potency and purity.

Akkermansia muciniphila is considered safe for most people, especially in its pasteurized form. Clinical trials have not reported serious side effects, but potential mild reactions may include:

If you’re pregnant, breastfeeding or managing a chronic condition, consult a healthcare provider before starting Akkermansia probiotic supplements.

Akkermansia muciniphila helps maintain the gut lining, supports metabolic health, and may reduce inflammation and support weight management.

Yes, though it’s a newer type of probiotic that differs from traditional strains. It’s not found in food but is available in supplement form.

Polyphenol-rich foods (berries, green tea), prebiotic fibers (onion, garlic), probiotic foods (yogurt, kefir) and healthy fats (omega-3s) support its growth.

Yes, pasteurized Akkermansia supplements have been shown to be safe and well-tolerated in human studies.

It may aid weight management by supporting metabolism, reducing inflammation and improving insulin sensitivity.

There is currently no evidence that Akkermansia muciniphila overgrowth is harmful. However, balance is key in any microbiome. Supplementation should be done under professional guidance.

Yes, cranberry extract is rich in polyphenols that have been shown in studies to boost levels in the gut.

You can’t directly get Akkermansia muciniphila from food, since it naturally lives in the mucus layer of the gut and isn’t found in typical dietary sources. However, certain foods can help support its natural growth in your microbiome. These include foods high in prebiotic fiber (like garlic, onions and chicory root), polyphenol-rich foods (such as berries, pomegranate and green tea), probiotic foods (like kefir and yogurt), and omega-3 fats from sources like wild-caught salmon and chia seeds.

Eating these regularly may help create an environment where Akkermansia thrives naturally.

Emerging research suggests that a higher abundance of Akkermansia muciniphila may be linked to improved insulin sensitivity and reduced insulin resistance. This connection is likely due to its role in supporting gut barrier integrity and reducing low-grade inflammation, both of which can influence metabolic health. While early human studies are promising, more research is needed before Akkermansia can be considered a proven therapy for insulin resistance.

Some human research indicates that people with higher levels of Akkermansia muciniphila tend to have lower HbA1c levels, a marker of long-term blood sugar control. This may be related to the bacterium’s role in improving gut health and inflammation balance, which can indirectly support healthy glucose metabolism. However, more clinical trials are needed to determine whether directly increasing Akkermansia can consistently lower HbA1c in people with diabetes or prediabetes.